BriaCell Therapeutics Corp. (BCTX)

USD 0.62

(-4.58%)

Market Cap (In USD)

27.22 Million

Revenue (In USD)

-

Net Income (In USD)

-4.79 Million

Avg. Volume

3.74 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.46-5.97
PE
-
EPS
-
Beta Value
1.816
ISIN
CA1079301091
CUSIP
10778Y302
CIK
1610820
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. William V. Williams M.D.
Employee Count
-
Website
https://www.briacell.com
Ipo Date
2012-03-14
Details
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.